Funding Opportunity RFA-DK-25-016 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) requests applications for Polycystic Kidney Disease (PKD) Research and Translation Core Centers (RTCC). The RTCCs are expected to work collaboratively with the Central Coordinating Site (CCS) as part of a PKD Research Consortium and serve as a national resource for the larger research community. The RTCCs should develop and share research resources (e.g. reagents, tools etc.), services and expertise that would be difficult or impractical to support in individual labs. The NOFO is open to new applications, not renewals. Previously funded PKD Centers may apply as new centers.

Funding Opportunity RFA-DK-25-015 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) requests applications for the Central Coordinating Site (CCS) for the Polycystic Kidney Disease (PKD) Research Core Centers (RTCC). The CCS is expected to work collaboratively with four RTCCs as part of the PKD Research Consortium and serve as a national resource for the larger research community. The CCS will provide central administrative and communications support for the Consortium. All activities within the Consortium are expected to address the overall goal of improving our understanding of the pathogenesis, progression, prevention and clinical management of PKD through enhanced sharing of resources and establishment of a robust research community. This NOFO is a companion announcement to RFA-DK-25-016:Polycystic Kidney Disease Research and Translation Core Centers (U54).

Notice NOT-CA-24-094 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-090 from the NIH Guide for Grants and Contracts

Notice NOT-LM-24-003 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-25-026 from the NIH Guide for Grants and Contracts. The goal of this Notice of Funding Opportunity (NOFO) is to support research to investigate mitochondrial-nuclear communication in the context of neurobiology and Alzheimer's disease and AD-related dementias (AD/ADRD). This research will transform our understanding of how mitochondrially derived metabolites can impact nuclear gene expression and how changes to nuclear function can impact mitochondrial activity. This has the potential to serve as the foundation for the development of future AD/ADRD therapies that specifically target mitochondrial function as well as shed light on the role that mitochondria play in aging and neurodegeneration.

Funding Opportunity RFA-CA-24-025 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to provide the infrastructure for early-phase cancer prevention clinical trials through the Cancer Prevention Clinical Trials Network (CP-CTNet), DCP's main mechanism for early clinical development of cancer preventive interventions. The phase 0-2 trials performed through CP-CTNet evaluate biologic effects of interventions and determine clinically relevant correlates, with the ultimate goal of advancing their further development for cancer prevention. The research network will develop multiple cancer prevention clinical trials targeting cancers arising in various organ sites, including collaborative studies across the Network, using the UG1 cooperative agreement funding mechanisms. This NOFO relates to the data management, auditing and statistical center that provides database support, auditing functions, statistical support, and coordinating functions for the network.

Funding Opportunity RFA-CA-24-024 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to provide the infrastructure for early-phase cancer prevention clinical trials through the Cancer Prevention Clinical Trials Network (CP-CTNet), DCP's main mechanism for early clinical development of cancer preventive interventions. The phase 0-2 trials performed through CP-CTNet evaluate biologic effects of interventions and determine clinically relevant correlates, with the ultimate goal of advancing their further development for cancer prevention. The research network will develop multiple cancer prevention clinical trials targeting cancers arising in various organ sites, including collaborative studies across the Network, using the UG1 cooperative agreement funding mechanisms. This NOFO relates to the performance sites that will plan and perform clinical trials.

Funding Opportunity PAR-24-260 from the NIH Guide for Grants and Contracts. The purpose of the Tribal Institutional Review Board Establishment and Enhancement (TIRBEE) award is to support federally recognized American Indian/Alaska Native (AI/AN) Tribes, Tribal colleges and universities, Tribal health programs, or Tribal organizations(collectively, eligible Tribal entities) to establish Institutional Review Boards (IRBs) or enhance the capacity of existing Tribal IRBs.

Notice NOT-RM-24-012 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AT-24-011 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to solicit UG3/UH3 phased award research applications to conduct efficient, large-scale pragmatic clinical trial and/or implementation science Demonstration Projects within the infrastructure of the NIH-DoD-VA Pain Management Collaboratory (PMC) on non-opioid approaches to pain management and other comorbid conditions in U.S. veterans, military personnel, and their families. Additional emphasis on a whole person approach to pain management will be added as a priority for NCCIH and partnering ICOs will also add their priority areas that include pain. This NOFO will add a trial supported by the HEAL Initiative, an NIH-wide research effort aimed at addressing the opioid epidemic in part by identifying effective, non-opioid pain management solutions. The PMC established a Coordinating Center in 2017 that provides national leadership and technical expertise for all aspects of PMC research including assistance to Demonstration Project grant awardees.

Notice NOT-RM-24-011 from the NIH Guide for Grants and Contracts

Notice NOT-GM-24-046 from the NIH Guide for Grants and Contracts

Notice NOT-NS-24-075 from the NIH Guide for Grants and Contracts

Notice NOT-AR-24-019 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-25-024 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) seeks to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will comprehensively interrogate fundamental biological mechanisms underlying HIV-associated comorbidities, co-infections, and complications relevant to the mission of the NIDDK and advance progress toward preventing or alleviating them.

Funding Opportunity PAR-24-267 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support projects which exploit genome or epigenome editing to functionally validate and characterize genes or variants involved in substance use disorder-relevant phenotypes. It is expected that any genetic resources generated will be made broadly available to the scientific community to enable investigation of the relevant neurobiological mechanisms involved and provide critical foundational knowledge for the development of future prevention, diagnostic, and therapeutic strategies.

Notice NOT-DE-25-032 from the NIH Guide for Grants and Contracts

Notice NOT-DK-24-028 from the NIH Guide for Grants and Contracts

Notice NOT-AI-24-059 from the NIH Guide for Grants and Contracts